Evidence map›Paper›PMID 32240532›Full record

ArticlePharmacoEconomics - open2020

Is Protocolised Weaning that Includes Early Extubation Onto Non-Invasive Ventilation More Cost Effective Than Protocolised Weaning Without Non-Invasive Ventilation? Findings from the Breathe Study.

Iftekhar Khan, Mandy Maredza, Melina Dritsaki, Dipesh Mistry, Ranjit Lall, Sarah E Lamb, Keith Couper, Simon Gates, Gavin D Perkins, Stavros Petrou and 1 more

Abstract read
In one paragraph

Article in PharmacoEconomics - open, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Guideline
  3. Trial
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Iftekhar KhanWarwick Clinical Trials Unit, University of Warwick, Coventry, CV4 7AL, UK. i.khan.2@warwick.ac.uk.
Mandy MaredzaWarwick Clinical Trials Unit, University of Warwick, Coventry, CV4 7AL, UK.
Melina DritsakiCentre for Statistics in Medicine, University of Oxford, Oxford, OX3 9DU, UK.
Dipesh MistryWarwick Clinical Trials Unit, University of Warwick, Coventry, CV4 7AL, UK.
Ranjit LallWarwick Clinical Trials Unit, University of Warwick, Coventry, CV4 7AL, UK.
Sarah E LambWarwick Clinical Trials Unit, University of Warwick, Coventry, CV4 7AL, UK.
Keith CouperWarwick Clinical Trials Unit, University of Warwick, Coventry, CV4 7AL, UK.
Simon GatesWarwick Clinical Trials Unit, University of Warwick, Coventry, CV4 7AL, UK.
Gavin D PerkinsWarwick Clinical Trials Unit, University of Warwick, Coventry, CV4 7AL, UK.
Stavros PetrouWarwick Clinical Trials Unit, University of Warwick, Coventry, CV4 7AL, UK.
Breathe collaborators

Funding

Health Technology Assessment Programme 10/134
6 · The paper itself

Abstract

backgroundOptimising techniques to wean patients from invasive mechanical ventilation (IMV) remains a key goal of intensive care practice. The use of non-invasive ventilation (NIV) as a weaning strategy (transitioning patients who are difficult to wean to early NIV) may reduce mortality, ventilator-associated pneumonia and intensive care unit (ICU) length of stay.

objectivesOur objectives were to determine the cost effectiveness of protocolised weaning, including early extubation onto NIV, compared with weaning without NIV in a UK National Health Service setting.

methodsWe conducted an economic evaluation alongside a multicentre randomised controlled trial. Patients were randomised to either protocol-directed weaning from mechanical ventilation or ongoing IMV with daily spontaneous breathing trials. The primary efficacy outcome was time to liberation from ventilation. Bivariate regression of costs and quality-adjusted life-years (QALYs) provided estimates of the incremental cost per QALY and incremental net monetary benefit (INMB) overall and for subgroups [presence/absence of chronic obstructive pulmonary disease (COPD) and operative status]. Long-term cost effectiveness was determined through extrapolation of survival curves using flexible parametric modelling.

resultsNIV was associated with a mean INMB of £620 ($US885) (cost-effectiveness threshold of £20,000 per QALY) with a corresponding probability of 58% that NIV is cost effective. The probability that NIV is cost effective was higher for those with COPD (84%). NIV was cost effective over 5 years, with an estimated incremental cost-effectiveness ratio of £4618 ($US6594 per QALY gained).

conclusionsThe probability of NIV being cost effective relative to weaning without NIV ranged between 57 and 59% overall and between 82 and 87% for the COPD subgroup.

Identifiers

PMID32240532
PMCPMC7223248

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.